UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005121
Receipt number R000006088
Scientific Title The combined therapy of Montelukast plus H1-antihistamine for for moderate to severe Japanese cedar pollinosis and its clinical efficasy
Date of disclosure of the study information 2011/02/22
Last modified on 2011/09/05 13:39:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The combined therapy of Montelukast plus H1-antihistamine for for moderate to severe Japanese cedar pollinosis and its clinical efficasy

Acronym

The combined therapy of Montelukast plus H1-antihistamine tion for for for Japanese cedar pollinosis and its clinical efficasy

Scientific Title

The combined therapy of Montelukast plus H1-antihistamine for for moderate to severe Japanese cedar pollinosis and its clinical efficasy

Scientific Title:Acronym

The combined therapy of Montelukast plus H1-antihistamine tion for for for Japanese cedar pollinosis and its clinical efficasy

Region

Japan


Condition

Condition

Japanese cedar pollinosis

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We examimned the efficacy of combined therapy using Montelukast and H1-antihistamine for moderate to severe Japanese cedar pollinosis with, a randomized, double-blined, placebo-controlled study during pollen-season.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase IV


Assessment

Primary outcomes

The combined therapy of Montelukast plus H1-antihistamine

Key secondary outcomes

Nitric oxide consentration in upper airway


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

It is given montelukast 10mg plus loratadine 10 mg per 1 day, during Japanese pollen season.

Interventions/Control_2

It is given montelukast 10mg plus placebo per 1 day, during Japanese pollen season.

Interventions/Control_3

It is given montelukast 10mg plus placebo per 1 day, during Japanese pollen season.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

Being over class 2 in CAP-RAST against Japanese Cedar pollen over, and having clinicalsymptoms during Japanese cedar pollen season.

Key exclusion criteria

Pregnancy, potential pregnancy, and breas-feeding patient.

Target sample size

180


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shigeharu Fujieda

Organization

Faculty of Medicine, University of Fukui

Division name

Ororhinolaryngology, Head and Neck Surgery

Zip code


Address

23 Matsuoka-Shimoaizuki, Eiheiji, Yoshida, Fukui, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Takechiyo Yamada

Organization

Faculty of Medicine, University of Fukui

Division name

Ororhinolaryngology, Head and Neck Surgery

Zip code


Address


TEL


Homepage URL


Email

ymdtkcy@gmail.com


Sponsor or person

Institute

Faculty of Medicine, University of Fukui

Institute

Department

Personal name



Funding Source

Organization

Ororhinolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Fukui

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 02 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 01 Month 25 Day

Date of IRB


Anticipated trial start date

2011 Year 02 Month 01 Day

Last follow-up date

2011 Year 04 Month 01 Day

Date of closure to data entry

2011 Year 05 Month 01 Day

Date trial data considered complete

2011 Year 05 Month 01 Day

Date analysis concluded

2011 Year 08 Month 01 Day


Other

Other related information



Management information

Registered date

2011 Year 02 Month 22 Day

Last modified on

2011 Year 09 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006088


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name